Literature DB >> 3661167

The effects of deferoxamine mesylate and hypoxia on the cochlea.

M Shirane1, R V Harrison.   

Abstract

Deferoxamine mesylate (DF) is a chelating agent used for the treatment of iron overload. Recently audiological testing of patients on long-term treatment with this drug indicated the possibility of an ototoxic side effect (1). We administered DF to chinchillas with both acute and chronic regimes. Functional and histological damage to the cochlea was detected only in the acute experiment. This was assumed to come not from the direct effect of DF on the cochlea but from the hypoxia as a result of respiratory suppression due to DF toxicity. To confirm this, animals were exposed to hypoxia during the same time course as for the DF experiment. Histological and physiological consequences of this hypoxia alone revealed very similar results to that observed in the acute DF experiment. This implies that DF has little direct toxic effect on the cochlea and, more importantly that considerable attention to hypoxia should be paid when assessing the cochlear pathology of animals which have been subjected to general anesthesia for long periods.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3661167     DOI: 10.3109/00016488709109053

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  5 in total

Review 1.  Deferoxamine (desferrioxamine). New toxicities for an old drug.

Authors:  Y Bentur; M McGuigan; G Koren
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 2.  Experimental, clinical and preventive aspects of ototoxicity.

Authors:  A A Chiodo; P W Alberti
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

3.  Frequency of sensory neural hearing loss in major Beta-thalassemias in southern iran.

Authors:  Abolhassan Faramarzi; Mehran Karimi; Seyed-Taghi Heydari; Mahmoud Shishegar; Masoud Kaviani
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

4.  Early Enzyme Replacement Therapy Improves Hearing and Immune Defects in Adenosine Deaminase Deficient-Mice.

Authors:  Xiaobai Xu; Jaina Negandhi; Weixian Min; Michael Tsui; Martin Post; Robert V Harrison; Eyal Grunebaum
Journal:  Front Immunol       Date:  2019-03-13       Impact factor: 7.561

5.  Desferioximine induced Ototoxicity in Thalassemic patients.

Authors:  Dharam Vir; N K Panda; R K Marwaha
Journal:  Ann Neurosci       Date:  2010-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.